Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

4.29USD
8:59pm GMT
Change (% chg)

$-0.17 (-3.81%)
Prev Close
$4.46
Open
$4.47
Day's High
$4.49
Day's Low
$4.19
Volume
998,860
Avg. Vol
986,722
52-wk High
$33.61
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Akorn Q3 Gaap Loss Per Share $0.56
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Akorn Inc ::AKORN PROVIDES THIRD QUARTER 2018 RESULTS.Q3 GAAP LOSS PER SHARE $0.56.Q3 REVENUE $165.6 MILLION VERSUS I/B/E/S VIEW $184.2 MILLION.Q3 EARNINGS PER SHARE VIEW $0.11 -- THOMSON REUTERS I/B/E/S.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.06 INCLUDING ITEMS.  Full Article

Akorn Appeals Fresenius Kabi Ruling
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Akorn Inc ::AKORN APPEALS FRESENIUS KABI RULING.HAS ALSO FILED A MOTION SEEKING EXPEDITED PROCEEDINGS IN ITS APPEAL."DISAGREES WITH OPINION ISSUED OCTOBER 1 BY COURT OF CHANCERY".  Full Article

Akorn Comments On Delaware Chancery Court Ruling
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akorn Inc ::AKORN COMMENTS ON DELAWARE CHANCERY COURT RULING.AKORN INC - "CONTINUE TO BELIEVE FRESENIUS' ATTEMPT TO TERMINATE TRANSACTION IS IN BREACH OF OUR BINDING MERGER AGREEMENT".AKORN INC - "INTEND TO APPEAL, IN AN EFFORT TO VIGOROUSLY ENFORCE OUR RIGHTS".  Full Article

Fresenius CEO Expects Akorn Matter To Be Resolved By Early 2019
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Fresenius Se ::CEO SAYS ARE CONVINCED OF MERITS OF CASE TO TERMINATE AKORN DEAL.CEO SAYS EVEN IF COURT DOES NOT AGREE IT WAS THE RIGHT DECISION TO TERMINATE DEAL.CEO SAYS EXPECTS AKORN MATTER TO BE FINALLY RESOLVED BY EARLY NEXT YEAR.CFO SAYS LESS LIKELY TO REACH UPPER END OF 2018 SALES GUIDANCE OF 5-8 PERCENT.CEO SAYS IF WE ARE FORCED TO CLOSE AKORN DEAL, WILL NEED TO DO SOME PRETTY SUBSTANTIAL REMEDIATION REGARDLESS OF HOW FDA RESPONDS.  Full Article

Akorn Issues Statement In Response To Fresenius Seeking To Terminate Merger
Sunday, 22 Apr 2018 

April 22 (Reuters) - Akorn Inc ::AKORN INC ISSUES STATEMENT IN RESPONSE TO FRESENIUS KABI’S ANNOUNCEMENT THAT IT IS SEEKING TO TERMINATE THE DEFINITIVE MERGER AGREEMENT.AKORN SAYS PREVIOUSLY DISCLOSED ONGOING INVESTIGATION HAS NOT FOUND ANY FACTS THAT WOULD RESULT IN ADVERSE EFFECT ON CO'S BUSINESS.AKORN SAYS SINCE INVESTIGATION DID NOT FIND ANY FACTS RESULTING IN ADVERSE EFFECT ON CO'S BUSINESS, IT IS "NO BASIS TO TERMINATE THE TRANSACTION".AKORN SAYS INTEND TO "VIGOROUSLY" ENFORCE CO'S RIGHTS, AND FRESENIUS’ OBLIGATIONS, UNDER BINDING MERGER AGREEMENT.  Full Article

Fresenius SE & Co. KGaA Fresenius Terminates Merger Agreement With Akorn
Sunday, 22 Apr 2018 

April 22 (Reuters) - Fresenius SE & Co KGaA ::DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS TERMINATES MERGER AGREEMENT WITH AKORN.  Full Article

SEC Says Akorn Inc Agrees To Settle To Reporting, Accounting Control Violations
Monday, 26 Mar 2018 

March 26 (Reuters) - Akorn Inc ::SEC SAYS AKORN INC AND ITS FORMER CFO AND CONTROLLER AGREE TO SETTLE TO REPORTING AND ACCOUNTING CONTROL VIOLATIONS.SEC - AKORN INC, FORMER CFO & CONTROLLER AGREED TO SETTLE THE CHARGES WITHOUT ADMITTING OR DENYING THE COMMISSION'S ALLEGATIONS.  Full Article

Fresenius confirms discussions concerning potential acquisition of Akorn
Friday, 7 Apr 2017 

Fresenius Se : Co and Akorn Inc don't intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so . Currently in discussions with Akorn concerning a potential acquisition of Akorn . Confirms that Fresenius Kabi is currently in discussions with Akorn Inc concerning a potential acquisition of Akorn .No assurance any transaction will result from these discussions or as to terms of any such transaction.  Full Article

Fresenius said to weigh a bid for U.S. generics maker Akorn - Bloomberg
Friday, 7 Apr 2017 

:Fresenius said to weigh a bid for U.S. generics maker Akorn - Bloomberg.  Full Article

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .